Truist Securities Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $35

Truist Securities analyst Richard Newitter upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold to Buy and raises the price target from $27 to $35.